BOVINE RESPIRATORY SYNCYTIAL VIRUS AS A HUMAN VACCINE

牛呼吸道合胞病毒作为人类疫苗

• 批准号: 2069815
• 负责人: GREGORY A. PRINCE
• 金额: $ 5万
• 依托单位: SIGMODON SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-09-30 至 1994-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2069815
• 关键词: Rodentias; drug screening /evaluation; live vaccine; nonhuman therapy evaluation; respiratory disorder chemotherapy; respiratory syncytial virus

Despite efforts spanning three decades, there is no licensed vaccine against respiratory syncytial virus (RSV), the most important cause of infant pulmonary disease worldwide. Bovine respiratory syncytial virus (BRSV) is antigenically related to RSV, causes no significant pathology in laboratory animals, and confers highly significant protection against RSV infection in seronegative animals. It appears not to cause potentiated disease, unlike previous candidate vaccines. Because virtually all potential recipients of an RSV vaccine would be infants possessing substantial amounts of maternally derived antibody to RSV, and because such antibody has been shown to block the efficacy of other candidate vaccines, the specific aim of this proposal is to test the efficacy and safety of BRSV in cotton rats previously administered human RSV antibody in amounts equivalent to those seen in human infants. If BRSV protects against RSV under these conditions, followup studies would include clinical trials.

尽管跨过三十年的努力，但没有持牌疫苗 反对呼吸道合胞病毒（RSV），这是最重要的原因 全世界婴儿肺部疾病。牛呼吸道合胞病毒 （BRSV）与RSV抗原相关，在 实验室动物，并赋予对RSV的高度重大保护 血清神经动物感染。它似乎不会导致增强 疾病，与以前的候选疫苗不同。因为几乎全部 RSV疫苗的潜在接受者将是拥有的婴儿 大量对RSV的母体衍生抗体，因为 这种抗体已被证明可以阻止其他候选者的功效 疫苗，该提案的具体目的是测试功效和 BRSV在先前给予人RSV抗体的棉花大鼠中的安全性 等同于人类婴儿所见的数量。如果BRSV保护 在这些条件下针对RSV，后续研究将包括 临床试验。